Dr. Wan Lam's Laboratory is primarily focused on understanding the molecular events that lead to cancer progression. His team has developed novel whole genome technologies and bioinformatics methodologies for tracking genetic, epigenetic, and gene expression changes in order to identify genes and signaling pathways that govern cancer progression and treatment response processes. He studies a variety of cancer types, with emphasis on lung cancer. His internationally recognized molecular systems biology team has discovered actionable pathways uniquely disrupted in the squamous cell carcinoma, adenocarcinoma, and small cell lung carcinoma subtypes of lung cancer. His team has also identified coding and non-coding RNA gene disruptions that link COPD and lung cancer, predict drug sensitivity in malignancy, and elucidate the diverse mechanisms of lung cancer development in smokers, former smokers, and non-smokers.
Wan Lam Lab
Dr. Wan Lam, PhD
Deputy Head of Integrative Oncology
Dr. Kim Lonergan
Dr. Greg Stewart, PhD
Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma.
Nature communications, 2019
Discovery of Previously Undetected MicroRNAs in Mesothelioma and Their Use as Tissue-of-Origin Markers.
American journal of respiratory cell and molecular biology, 2019
Previously undescribed thyroid-specific miRNA sequences in papillary thyroid carcinoma.
Journal of human genetics, 2019
Beyond sequence homology: Cellular biology limits the potential of XIST to act as a miRNA sponge.
PloS one, 2019
Aberrant Expression of Pseudogene-Derived lncRNAs as an Alternative Mechanism of Cancer Gene Regulation in Lung Adenocarcinoma.
Frontiers in genetics, 2019
Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence.
Journal for immunotherapy of cancer, 2019
Large-scale discovery of previously undetected microRNAs specific to human liver.
Human genomics, 2018
Environmental arsenic exposure: From genetic susceptibility to pathogenesis.
Environment international, 2018
Somatic mutation-associated T follicular helper cell elevation in lung adenocarcinoma.
Expanding the miRNA Transcriptome of Human Kidney and Renal Cell Carcinoma.
International journal of genomics, 2018
cGAS-STING and Cancer: Dichotomous Roles in Tumor Immunity and Development.
Trends in immunology, 2018
Small non-coding RNA transcriptome of the NCI-60 cell line panel.
Scientific data, 2017
DLK1-DIO3 imprinted locus deregulation in development, respiratory disease, and cancer.
Expert review of respiratory medicine, 2017
Deregulation of small non-coding RNAs at the DLK1-DIO3 imprinted locus predicts lung cancer patient outcome.
Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis.
Molecular cancer, 2016
Piwi-interacting RNAs in cancer: emerging functions and clinical utility.
Molecular cancer, 2016
Gene expression analysis of microtubule affinity-regulating kinase 2 in non-small cell lung cancer.
Genomics data, 2015
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.